News

We are excited to announce that our recently CE-marked MosaiQ® AiPlex CTD microarray immunoassay, which aims to shorten time-to-diagnosis for autoimmune patients, is now available in over 35 markets across Europe and the Asia Pacific region. The MosaiQ AiPlex CTD solution is designed to aid in the diagnosis of multiple Connective Tissue Diseases, including Systemic…

Our leadership team recently gathered to celebrate 2023 achievements and kick off the new year. As part of a highly energizing team-building activity, and to bring our environmental, social and governance commitments to life, the team built solar lamps that will be donated to children in energy-poor countries. Ensuring universal access to affordable and clean…

We are excited to share that our publication on the performance characteristics of our automated planar microarray immunoassay for the detection of antibodies against Centromere Protein B is now available in Immunochemistry & Immunopathology: https://www.hilarispublisher.com/open-access/performance-characteristics-of-a-novel-fully-automated-planar-microarray-immunoassay-for-the-detection-of-antibodies-against-centr-103431.html Would you like to know more about our MosaiQ solution? Click below to learn more:

AliveDx and Global Marketing Services (GMS) have signed distribution agreements, which will enable Global Marketing Services to distribute MosaiQ® and Alba products in Pakistan. The distribution agreements take effect immediately. This strategic partnership acts as a reminder of AliveDx’s commitment to growing and expanding its geographical reach. It will enable both parties to improve patient…

We are excited to announce that our abstract titled “Performance of a Novel, Fully-automated Multiplexed Immunoassay Microarray Prototype for Serological Detection of Eleven Autoantibodies Found in Connective Tissue Diseases” will be presented at the 25th Asia-Pacific League of Associations for Rheumatology Congress (APLAR 2023) in Chiang Mai, Thailand. Join us on Saturday, 9 December 2023,…

AliveDx and Bio-Strategy have signed distribution agreements, which will enable Bio-Strategy to distribute MosaiQ® products in Australia, New Zealand, and the Pacific Islands, and Alba products in New Zealand. The distribution agreements take effect immediately. This strategic partnership serves as a reminder of AliveDx’s unwavering dedication to developing and broadening its geographical presence. It will…

We are delighted to unveil The L.I.V.E. Xchange, our new showroom and innovation space, at our headquarters in Eysins, Switzerland. The L.I.V.E. Xchange was created to give our customers, development partners, distributors, and other stakeholders access to a dynamic environment that encourages collaboration and creativity by allowing ideas and innovation to flow freely. The new…

AliveDx and Rowad Medical Services have signed a distribution agreement, which will enable Rowad Medical Services to distribute AliveDx’s products, Alba and MosaiQ®, in the Kingdom of Saudi Arabia. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow and expand its geographical presence. It will enable both parties to…

Last week, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical teams. Our Golden Partners attended presentations, brainstorming sessions, and visited our manufacturing facilities. They also…

We are excited to announce that our abstract on the microarray prototype for the serological detection of eleven IgG autoantibodies commonly found in Connective Tissue Diseases was presented at ACR Convergence 2023, held in San Diego, California. Our poster titled “Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype forthe Serological Detectionof Eleven…